Value through Innovation27 July 2016

What is a lay summary?

To view this video in other translations click on the language below:
Chinese (simplified)
Chinese (traditional)
French
German
Italian
Japanese
Portuguese (Brazilian)
Spanish

Clinical Study Results

  • VARGATEF ® - Carcinoma, Hepatocellular
    Clinical Study Number 1199.39
    Study Indication Carcinoma, Hepatocellular
    Product VARGATEF ®
    Generic Name Nintedanib
    Lab Code
    Clinical Phase I/II
    Study Title

    A multicenter, open label, phase I/randomized II study to evaluate safety, pharmacokinetics and efficacy of BIBF 1120 in comparison with sorafenib for advanced hepatocellular carcinoma patients in Asia.

    Study Document
    Trial synopsis 1199.39 english
  • VARGATEF ® - Carcinoma, Hepatocellular
    Clinical Study Number 1199.37
    Study Indication Carcinoma, Hepatocellular
    Product VARGATEF ®
    Generic Name Nintedanib
    Lab Code
    Clinical Phase I/II
    Study Title

    A multicentre, open label, Phase I/randomised Phase II study to evaluate safety, pharmacokinetics and efficacy of BIBF 1120 in comparison with sorafenib for advanced hepatocellular carcinoma patients

    Study Document
    Trial synopsis 1199.37 english
  • VARGATEF ® - Carcinoma, Hepatocellular
    Clinical Study Number 1199.120
    Study Indication Carcinoma, Hepatocellular
    Product VARGATEF ®
    Generic Name Nintedanib
    Lab Code
    Clinical Phase I
    Study Title

    An open label, dose escalation phase I study to evaluate the safety and tolerability of continuous twice-daily oral treatment of nintedanib in Japanese patients with hepatocellular carcinoma

    Study Document
    Trial synopsis 1199.120_DR english